Clinical trials: Cancer Refractory
Male Breast Cancer, Recurrent Breast Cancer
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00425672
- Testing
- ONTAK, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Refractory or Recurrent Solid Tumors, Acute Myelogenous Leukemia
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Background: AZD2171 is an experimental drug that may slow the growth of cancers by blocking angiogenesis (formation of new blood vessels). Cancer growth is dependent on angiogenesis for nutrition.
- Trial name
- NCT00321581
- Testing
- Cediranib, AZD2171, RECENTIN
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
The purpose of this Phase II single-arm study is to evaluate the efficacy of Radium-223 in treating bone lesions from differentiated thyroid cancer that are I-131 refractory.
- Trial name
- RAD-THYR (NCT02390934)
- Testing
- Radium 223
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
B Cell Lymphoma
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
- Trial name
- NCT03101709
- Testing
- Cyclophosphamide, Fludarabine, CART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in…
- Trial name
- NCT02076009
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 145 sites in United States, Australia and 16 more
- Volunteers
- 569 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Multiple Myeloma
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
- Trial name
- NCT00912899
- Testing
- Noscapine HCl
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cougar Biotechnology, Inc.
Cancer
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor…
- Trial name
- NCT04669899
- Testing
- JTX-8064, pimivalimab
- Where
- 45 sites in United States
- Volunteers
- 190 people
- Sponsor
- Jounce Therapeutics, Inc.
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Soft Tissue Sarcoma (Excluding GIST)
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
The study is expected to include 24 patients with metastatic or surgically unresectable relapsed/refractory soft tissue sarcoma confirmed by histological evidence, who have received at least one line of systemic treatment…
- Trial name
- NCT07457775
- Testing
- Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Relapsed Or Refractory Multiple Myeloma
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated…
- Trial name
- NCT00545519
- Testing
- thymoglobulin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Triple Negative Breast Cancer
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
This is a multicenter translational study to understand therapeutic resistance in patients undergoing standard chemotherapy for triple negative breast cancer.
- Trial name
- NCT01276899
- Testing
- Needle core biopsies, Needle core biopsies of metastatic lesion
- Where
- 8 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Jewish General Hospital
Breast Cancer, Non-Small Cell Lung Cancer
131-I-TM-601 Study in Adults With Solid Tumors
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with recurrent or refractory primary…
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer
- Trial name
- NCT00379132
- Testing
- 131-I-TM-601 (chlorotoxin)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- TransMolecular
Lymphoma
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.
- Trial name
- NCT05891821
- Testing
- Balstilimab
- Where
- Armenia
- Volunteers
- 20 people
- Sponsor
- Immune Oncology Research Institute
Acute Myeloblastic Leukemia, Lymphoblastic Leukemia
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.
- Conditions
- Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- GLOBAL (NCT00354120)
- Testing
- Alentuzumab, Globulina antilinfocitaria
- Where
- 22 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Leukemia
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia.
- Trial name
- NCT00021983
- Testing
- BL22 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Large B-cell Lymphoma
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease.
- Trial name
- NCT07052305
- Testing
- NT-I7, CAR T-cell therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Solid Tumor, Adult
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in…
- Trial name
- NCT06026254
- Testing
- IMSA101, Immune Checkpoint Inhibitor
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Mantle Cell Lymphoma
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free…
- Trial name
- NCT06324994
- Testing
- Linperlisib in combination with Obinutuzumab and Venetoclax
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Dalian Medical University
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04579224
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 448 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.